The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
mediaposted on 2021-03-26, 16:23 authored by Adis journals on behalf of, Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, Niels Ejskjaer
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.